DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Dawn - 1 Megan Jelinger - 1 Michael Sen - 1 Danish drugmaker - 1 Neil Unmack - 1 Oliver Taslic - 1
Top related locs:
Findlay , Ohio U.S Germany Fresenius Vamed Danish
Top related orgs:
REUTERS - 1 Novo Nordisk - 1 Denmark’s Novo Nordisk - 1 Fresenius - 1 Thomson - 1

Search resuls for: "Vamed"


4 mentions found


☆ Obesity revolution gorges on dialysis maker
  + stars: | 2023-10-11 | by ( Aimee Donnellan | ) www.reuters.com   time to read: +3 min
REUTERS/Megan Jelinger Acquire Licensing RightsLONDON, Oct 11 (Reuters Breakingviews) - Kidney dialysis kit-makers look set to be the latest victim of the obesity drug boom. On Wednesday, shares in Germany-listed Fresenius Medical Care (FMEG.DE) fell 20% after a medical trial showed a Novo Nordisk (NOVOb.CO) drug can reduce the risk of kidney failure. Diabetes and obesity drugs are showing their fringe benefits. In a recent drug trial, Wegovy, an obesity remedy made by Denmark’s Novo Nordisk, reduced the incidence of serious cardiovascular events like strokes and heart attacks by 20% in overweight patients. The collapse in Fresenius Medical Care’s share price looks appropriate.
Persons: Dawn, Megan Jelinger, Michael Sen, Danish drugmaker, Neil Unmack, Oliver Taslic Organizations: REUTERS, Reuters, Novo Nordisk, Denmark’s Novo Nordisk, Fresenius, Thomson Locations: Findlay , Ohio, U.S, Germany, Fresenius, Vamed, Danish
☆ Fresenius Medical's operating profit drops less than feared as labour shortages ease
  + stars: | 2023-05-09 | by ( Ludwig Burger | ) www.reuters.com   time to read: +2 min
FRANKFURT, May 9 (Reuters) - Fresenius Medical Care (FMEG.DE) said on Tuesday labour shortages were slowly easing as the German dialysis specialist reported a drop in its first-quarter adjusted operating income, although not as steep as feared by some analysts. The company said in a statement on Tuesday its adjusted operating income dropped to 354 million euros ($390 million), compared with the median analysts' estimate of 335 million in a consensus posted on the company's website. The dialysis group's parent Fresenius SE (FREG.DE) has said this year it would cede control over the struggling dialysis firm, but keep its stake for now as part of a turnaround plan. Fresenius Medical, which was hit hard by a high rate of COVID-19 deaths among its patients, said this burden was easing, though excess mortality for now continued to weigh on growth. Its parent company, German healthcare group Fresenius (FREG.DE), said on Tuesday its first-quarter operating earnings slipped a currency-adjusted 10%.
☆ Germany's FMC buoyed by Fresenius plan to cede control
  + stars: | 2023-02-22 | by ( Ludwig Burger Patricia Weiss | Ludwig Burger | Patricia Weiss | ) www.reuters.com   time to read: +4 min
Healthcare group Fresenius (FREG.DE) said late on Tuesday it would give up strategic control over FMC via a planned change of the division's legal form, also releasing annual results and an outlook that failed to impress investors. Fresenius CEO Michael Sen, a former E.ON (EONGn.DE) and Siemens (SIEGn.DE) executive who took over the helm in October, wants to simplify the company's structure but said he will hang onto the 32% stake Fresenius owns in FMC. This makes a sale more likely in the future, said Florian Oberhofer, portfolio manager at Union Investment, which holds 0.26% of Fresenius shares. Sen said Fresenius was banking on a business improvement at FMC and Vamed and on participating financially in this through its holdings in both. FMC and Fresenius shares lagReporting by Ludwig Burger and Patricia Weiss; Additional reporting by Christoph Steitz; Writing by Rachel More; Editing by Josephine Mason, Elaine Hardcastle and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.
☆ Fresenius takes tentative step on road to breakup
  + stars: | 2023-02-22 | by ( ) www.reuters.com   time to read: +2 min
On Tuesday evening the $17 billion German medical technology company said it will relinquish control of its listed dialysis firm, Fresenius Medical Care (FMEG.DE), in order to focus on its core businesses. Fresenius currently controls the dialysis business and can appoint its board despite only owning a 32% stake, thanks to its arcane German legal structure. The news sent Fresenius Medical Care stock up around 12% on Wednesday. His core intravenous drugs and hospital operating divisions should be worth 20 billion euros each, according to the UK bank. That implies a total value for the group including debt of 48 billion euros, far above its current 40 billion euro enterprise value.
0 next >>
Total: 4